Participated · Series A · May 2024

Welbe is a Mexico City-based healthtech company that provides employers with a comprehensive health ecosystem through an intelligent occupational health management system. Its offering is coupled with a minor medical expense program that generates data to help reduce medical costs and employee absenteeism. Led by CEO Eduardo Medeiros Cardoso, Welbe packages these services for companies to take care of their employees. The company plans to use new funding to expand operations and accelerate product development. Welbe recently raised $7M in a Series A to support its growth plans.

Participated · Series A · Jul 2023

SiPhox Health develops silicon photonic chip–based diagnostics to bring lab-grade blood testing into the home. Founded in 2020 by MIT scientists Diedrik Vermeulen and Michael Dubrovsky, the company was part of Y Combinator's summer 2020 cohort and is based in Burlington, Massachusetts. Today it runs mail-in testing using conventional lab technology and sells a kit that measures 17 biomarkers across inflammation, cardiovascular, metabolic, and hormone panels for $95 plus a $16 monthly membership. Its first product was a $1 COVID-19 test on a disposable cartridge; the company is developing the SiPhox Home finger-prick device to miniaturize testing onto silicon chips and deliver protein and hormone results in five minutes or less. SiPhox Health is targeting U.S. FDA clearance for SiPhox Home within a year and is preparing a case study with thousands of participants. The startup has about 30 employees and reports early signs of chronic disease, such as pre-diabetes, in roughly 20% of tests.

Participated · Series A · Aug 2022

ISA Saúde operates a digital platform that enables hospital-level services to be delivered in patients’ homes, replacing care that would traditionally occur in brick-and-mortar facilities. The company coordinates a network of more than 4,000 healthcare professionals and currently treats roughly 1,500 patients per day across 60 Brazilian cities. By integrating structural clinical data and artificial intelligence, ISA Saúde seeks to generate predictive insights and streamline the patient journey. With fresh capital, the company intends to triple the number of cities it serves and broaden its range of care lines. Its tech-enabled model positions it to capture growing demand for convenient, cost-effective healthcare in Brazil. The business is financed by venture investors and most recently secured a US$30 million Series B round to fuel geographic and product expansion.

Participated · Series A · Jul 2021

Sweetch is an Israeli company that builds an AI-driven behavior-change app which analyzes smartphone “lifeprint” data to deliver hyper-personalized, emotionally intelligent reminders. The app times messages and modulates tone to increase the likelihood users follow clinical advice, and is distributed via partnerships with healthcare organizations, pharma, payers and providers rather than as an open app. Sweetch reports "tens of thousands of users" and about 45% of patients remain active after 24 months. In a 55-person prediabetes trial run at two Johns Hopkins Clinical Research Network sites, participants who completed the three-month study increased physical activity by an average of 2.8 MET-hours, lost ~1.6 kg, and reduced A1c by ~0.1%. The company has received NIH grant support to continue testing against gold-standard interventions and plans upcoming randomized controlled trials. Sweetch says it will use the Series A proceeds to expand into the U.S. and Brazil, grow its user base, and further tailor recommendations for additional conditions. Sweetch offers a patent-pending mobile app that assesses individuals' diabetes risk with a conversion time horizon and uses algorithms to guide users to the key objectives of the Diabetes Prevention Program. The product is intended for people at risk of developing diabetes or those who may be undiagnosed. Sweetch aligns its guidance with the clinically validated diet and exercise regimen associated with the Diabetes Prevention Program. The company planned to participate in a pilot study at Johns Hopkins Medicine in the first quarter of the year. The recent financing will support Sweetch's ambition to go to market in the U.S. and to be prescribed by doctors there, leveraging the Centers for Medicare and Medicaid decision to provide reimbursement for DPP participants. Leadership includes CEO Dana Chanan, CMO and business development lead Dr. Yossi Bahagon, and CTO Dan Lichtenfeld.